Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VBI Vaccines Inc VBIVQ

Healthcare Biotechnology
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.


GREY:VBIVQ - Post by User

VBI Vaccines Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by cypress44on Aug 06, 2018 6:21pm
244 Views
Post# 28418750

RE:RE:For whom the bell tolls

RE:RE:For whom the bell tolls

There was no report, just my 6-month chat with a finance friend specialising in Biotech, he is correct about VBI and now it has dropped below $2 earlier than expected. If it drops below $1.50 or even $1 due to a market correction or tax loss selling later in the year then we have real problems as shareholders.

The analyst target of $9.30 was given a while ago, VBI are not where they should be, what can the analysts amend it to? the stock has been on a slide since December 2017, they could give a target of $3 which is doable and about as useless as VBI management.
 

Yes they have cash but they are way behind, add 1 or 2 years to whatever they said initially for timings and that is probably the reality. Looking forward to company news and reading who will be issued new share options at a nice low price – look after the management, screw the shareholders


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities